Autoantibodies in patients with Alzheimer's disease: Pathogenetic role and potential use as biomarkers of disease progression

Autoimmunity Reviews

Volumn 9, Issue 12, 2010, Pages 807-811

  Colasanti, Tania ^a,b   Barbati, Cristiana ^a,b,d   Rosano, Giuseppe ^c   Malorni, Walter ^a,b   Ortona, Elena ^b  

^a Istituto San Raffaele Sulmona   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

Alzheimer's disease; Autoantibodies; Autoantigens; Biomarkers; Cerebrospinal fluid

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AUTOANTIBODY; FRUCTOSE BISPHOSPHATE ALDOLASE; GANGLIOSIDE GM1; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROTRANSMITTER; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN S100B; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ALZHEIMER DISEASE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; BRAIN NERVE CELL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; HUMAN; IMMUNE RESPONSE; MICROGLIA; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOGENESIS; PROTEIN FUNCTION; REVIEW;

ALZHEIMER DISEASE; AUTOANTIBODIES; BIOLOGICAL MARKERS; DEMENTIA; DISEASE PROGRESSION; HUMANS;

EID: 77956922920     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.07.008     Document Type: Review

References (42)

1. Cacabelos R., Fernandez-Novoa L., Lombardi V., Kubota Y., Takeda M. Molecular genetics of Alzheimer's disease and aging. Meth Find Exp Clin Pharmacol 2005, 27:1-573.
2. D'Andrea M.R. Add Alzheimer's disease to the list of autoimmune diseases. Med Hypotheses 2005, 64:458-463.
3. Weiner H.L., Selkoe D.J. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002, 420:879-884.
4. D'Andrea M.R. Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease. Brain Res 2003, 982:19-30.
5. Hardy J. Has the amyloid cascade hypothesis for AD been proved?. Curr Alzheimer Res 2006, 3:71-73.
6. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 2000, 924:17-25.
7. Szabo P., Relkin N., Weksler M.E. Natural human antibodies to amyloid beta peptide. Autoimmun Rev 2008, 7:415-420.
8. Kellner A., Matschke J., Bernreuther C., Moch H., Ferrer I., Glatzel M. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol 2009, 65:24-31.
9. Taguchi H., Planque S., Nishiyama Y., Szabo P., Weksler M.E., Friedland R.P., et al. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev 2008, 7:391-397.
10. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
11. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002, 22:6331-6335.
12. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
13. Dodel R.C., Du Y., Depboylu C., Hampel H., Frolich L., Haag A., et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75:1472-1474.
14. Geylis V., Steinitz M. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev 2006, 5:33-39.
15. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002, 32:1050-1060.
16. Bassett C.N., Neely M.D., Sidell K.R., Markesbery W.R., Swift L.L., Montine T.J. Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo. Lipids 1999, 34:1273-1280.
17. Binder C.J., Hörkkö S., Dewan A., Chang M., Kieu E.P., Goodyear C.S., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003, 9:736-743.
18. Kankaanpää J., Turunen S.P., Moilanen V., Hörkkö S., Remes A.M. Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer's disease. Neurobiol Dis 2009, 33:467-472.
19. Kakio A., Nishimoto S., Yanagisawa K., Kozutsumi Y., Matsuzaki K. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 2002, 41:7385-7390.
20. Yanagisawa K., Odaka A., Suzuki N., Ihara Y. GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer's disease. Nat Med 1995, 1:1062-1066.
21. Mandal P.K., Pettegrew J.W. Alzheimer's disease: NMR studies of asialo (GM1) and trisialo (GT1b) ganglioside interactions with Abeta (1-40) peptide in a membrane mimic environment. Neurochem Res 2004, 29:447-453.
22. Schott K., Wormstall H., Dietric M., Klein R., Batra A. Autoantibodies reactivity in serum of patients with Alzheimer's disease and other age-related dementias. Psychiatry Res 1996, 59:251-254.
23. Hatzifilippou E., Koutsouraki E., Banaki T., Traka M., Costa V.G., Baloyannis S.J. Antibodies against GM1 in demented patients. Am J Alzheimers Dis Other Demen 2008, 23:274-279.
24. Davydova T.V., Voskresenskaya N.I., Fomina V.G., Vetrile L.A., Doronina O.A. Induction of autoantibodies to glutamate in patients with Alzheimer's disease. Bull Exp Biol Med 2007, 143:182-183.
25. (25-35) oligomers, S100b and neurotransmitters. J Neuroimmunol 2007, 186:181-192.
26. Alisky J.M. Neurotransmitter depletion may be a cause of dementia pathology rather than an effect. Med Hypotheses 2006, 67:556-560.
27. Heizmann C.W., Fritz G., Schäfer B.W. S100 proteins: structure, functions and pathology. Front Biosci 2002, 7:1356-1368.
28. Petzold A., Keir G., Lim D., Smith M., Thompson E.J. Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern. Brain Res Bull 2003, 61:281-285.
29. Mecocci P., Parnetti L., Romano G., Scarelli A., Chionne F., Cecchetti R., et al. Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia. J Neuroimmunol 1995, 57:165-170.
30. Mor F., Izak M., Cohen I.R. Identification of aldolase as a target antigen in Alzheimer's disease. J Immunol 2005, 175:3439-3445.
31. Delunardo F., Margutti P., Pontecorvo S., Colasanti T., Conti F., Riganò R., et al. Screening of a microvascular endothelial cDNA library identifies rabaptin 5 as a novel autoantigen in Alzheimer's disease. J Neuroimmunol 2007, 192:105-112.
32. Neve R.L., Coopersmith R., McPhie D.L., Santeufemio C., Pratt K.G., Murphy C.J., et al. The neuronal growth-associated protein GAP-43 interacts with rabaptin-5 and participates in endocytosis. J Neurosci 1998, 18:7757-7767.
33. Nixon R.A. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging 2005, 26:373-382.
34. Nishimune H., Uyeda A., Nogawa M., Fujimori K., Taguchi T. Neurocrescin: a novel neurite-outgrowth factor secreted by muscle after denervation. NeuroReport 1997, 8:3649-3654.
35. Mruthinti S., Schade R.F., Harrell D.U., Gulati N.K., Swamy-Mruthinti S., Lee G.P., et al. Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: complication of diabetes. Curr Alzheimer Res 2006, 3:229-235.
36. Vacirca D, Delunardo F, Matarrese P, Colasanti T, Margutti P, Siracusano A, et al. Autoantibodies to the ATP synthase play a pathogenetic role in Alzheimer's disease. Neurobiol Aging 2010 [Jun 29, Electronic publication ahead of print].
37. Dahlstrom A., McRae A., Polinsky R., Nee L., Sadasivan B., Ling E.A. Alzheimer's disease cerebrospinal fluid antibodies display selectivity for microglia: investigations with cell cultures and human cortical biopsies. Mol Neurobiol 1994, 9:41-54.
38. McIntyre J.A., Hamilton R.L., DeKosky S.T. Redox-reactive autoantibodies in cerebrospinal fluids. Ann NY Acad Sci 2007, 1109:296-302.
39. McIntyre J.A., Chapman J., Shavit E., Hamilton R.L., Dekosky S.T. Redox-reactive autoantibodies in Alzheimer's patients' cerebrospinal fluids: preliminary studies. Autoimmunity 2007, 40:390-396.
40. Ounanian A., Guilbert B., Renversez J.C., Seigneurin J.M., Avrameas S. Antibodies to viral antigens, xenoantigens, and autoantigens in Alzheimer's disease. J Clin Lab Anal 1990, 4:367-375.
41. Singh V.K., Yang Y.Y., Singh E.A. Immunoblot detection of antibodies to myelin basic protein in Alzheimer's disease patients. Neurosci Lett 1992, 147:25-28.
42. Serot J.M., Bene M.C., Gobert B., Christmann D., Leheup B., Faure G.C. Antibodies to choroid plexus in senile dementia of Alzheimer's type. J Clin Pathol 1992, 45:781-783.